• Policy
• The HIRA launched a benefit review for Tabrecta
• by Lee, Tak-Sun Jun 21, 2022 05:54am

• Policy
• Drug price cut refund bill’s fate depends on LJC Chair
• by Lee, Jeong-Hwan Jun 20, 2022 06:04am

• Policy
• Hanmi obtains generic exclusivity for Dapalon Duo
• by Lee, Hye-Kyung Jun 20, 2022 06:03am

• Policy
• BA-linked listed drugs are about to be re-evaluated
• by Lee, Tak-Sun Jun 20, 2022 06:03am

• Policy
• Limited indications of JAKI for high-risk groups
• by Lee, Hye-Kyung Jun 20, 2022 06:02am

• Policy
• The KDCA is pushing for the introduction of Tecovirimat
• by Lee, Jeong-Hwan Jun 20, 2022 06:02am

• Policy
• Limited indications of JAKI for high-risk groups
• by Lee, Hye-Kyung Jun 16, 2022 05:58am

• Policy
• Listing period for new drugs to be reduced up to 60 days
• by Kim, Jung-Ju Jun 16, 2022 05:57am

• Policy
• Phase 2 of Shinpoong's Pyramax will be conducted again
• by Lee, Hye-Kyung Jun 16, 2022 05:57am

• Policy
• HIRA to review metformin+SGLT2+DPP4 reimb at last
• by Lee, Tak-Sun Jun 15, 2022 05:51am